Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of manfidokimab (AK120) in moderate-to-severe atopic dermatitis
CTR20241231Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of manfidokimab in atopic dermatitis (AD), sponsored by Akeso, Inc.. Started Apr 2024; status: completed.
02
Drugs
manfidokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20241231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241231.